Table 1.

Clinical outcomes and abscopal responses in clinical studies of melanoma with the combination of ipi and radiotherapy.

	Study type	N	Location	Modality	RT dose (Gy)/Fractions	ipi dosage	Median OS (months)	Abscopal response (%)	Toxicity ≥ Grade 3
Grimaldi [15]	Prospective	21	Various	SRS	30/10; 20–24/1	3 mg/kg/3 w	22,4	53	NR
Chandra [16]	Prospective	25	Various	SRS	26/4	3 mg/kg/3 w	28	25	NR
Theurich [17]	Prospective	45	Various	SBRT	Various	3 mg/kg/3 w	23,25	21	18,30%
Barker [20]	Prospective	29	Various	SBRT	24/1 (SBRT); Various (EBRT)	3–10 mg/kg/3 w	39	28	Not increased
Knisely [24]	Prospective	27	Brain	SRS	Not reported	NR	21,3	10	NR
Schoenfeld [18]	Retrospective	16	Brain	SRS	36 (WBRT); 22 (SRS)	3–10 mg/kg/3 w	18	63	Not increased
Koller [19]	Retrospective	70	Various	SBRT	NR	3 mg/kg/3 w	19	19,2	Not increased
Gerber [21]	Retrospective	13	Brain	WBRT	27–37.5/9–15	3–10 mg/kg/3 w	4	31	Not increased
Kropp [22]	Retrospective	16	Various	SBRT	Various	3 mg/kg/3 w	24	NR	Not increased
Qin [23]	Retrospective	44	Various	SBRT	Various	NR	21,8	NR	Not increased
Silk [25]	Retrospective	33	Brain	SRS	30–37/10–13 (WBRT); 14–24/1–5 (SRS)	3 mg/kg/3 w	18,3	NR	Not increased
Mathew [26]	Retrospective	25	Brain	SRS	15–20/1	3–10 mg/kg/3 w	5,9	NR	NR
Shoukat [27]	Retrospective	11	Brain	SRS	NR	NR	28	NR	Not increased
Kiess [28]	Retrospective	46	Brain	SRS	15–24/1	3–10 mg/kg/3 w	12,4	NR	20%
Tazi [29]	Retrospective	10	Brain	SRS	NR	NR	18	NR	10%
Patel [30]	Retrospective	20	Brain	SRS	15–21/1–5	3 mg/kg/3 w	12	NR	Not increased

RT = radiation therapy; ipi = ipilimumab; SBRT = stereotactic body radiation therapy; SRS = stereotactic radio surgery; NR = not reported.